Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adamis Pharmaceuticals Corporation    ADMP

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 0.77 USD in weekly data.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The stock is in a well-established, long-term rising trend above the technical support level at 0.77 USD
Weaknesses
  • The company has insufficient levels of profitability.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Other Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
ADAMIS PHARMACEUTICALS CORP..86.35%124
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ABBVIE INC.-0.42%188 420
ELI LILLY AND COMPANY22.55%187 971
NOVARTIS AG-6.52%186 338
MERCK & CO., INC.-10.60%185 042
NOVO NORDISK A/S1.90%157 942
BRISTOL-MYERS SQUIBB COMPAN..-4.34%135 392
AMGEN INC.-2.60%131 529
ASTRAZENECA PLC-6.38%124 268
SANOFI-1.68%115 133
GLAXOSMITHKLINE PLC-8.78%85 641
JIANGSU HENGRUI MEDICINE CO..-10.01%81 979
CHUGAI PHARMACEUTICAL CO., ..-18.15%68 397
More Results
Financials (USD)
Sales 2020 18,3 M - -
Net income 2020 -33,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,99x
Yield 2020 -
Capitalization 124 M 124 M -
Capi. / Sales 2020 6,80x
Capi. / Sales 2021 4,89x
Nbr of Employees 151
Free-Float 99,1%
Upcoming event on ADAMIS PHARMACEUTICALS CORPORATION
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability -
P/E ratio -
Potential -
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes